Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia in First Remission
1 trial -
Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia
1 trial -
Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax
AbbVie Deutschland GmbH & Co. KG
Chronic Lymphocytic Leukemia
1 trial -
Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia
1 trial -
Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use
AbbVie Deutschland GmbH & Co. KG
Higher-Risk Myelodysplastic Syndrome
1 trial -
Verzenios 150 mg film-coated tablets, EXEMESTANE, IBRANCE 75 mg film-coated tablets, Verzenios 100 mg film-coated tablets, FULVESTRANT, LETROZOLE, Camizestrant, IBRANCE 100 mg film-coated tablets, Saruparib, Verzenios 50 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, ANASTROZOLE
AstraZeneca AB
Advanced Breast Cancer
1 trial -
Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets
Hoffmann-La Roche
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet
The George Institute
Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.
The George Institute
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
The George Institute
Acute Myeloid Leukemia, ONCOLOGY
1 trial -
Vigabatrin
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Addiction
2 trials -
Vildagliptin
Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
1 trial -
Vildagliptin
Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
1 trial -
Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion
Hoffmann-La Roche
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
1 trial -
Viread 245 mg film-coated tablets, Viread 123 mg film-coated tablets, Viread 204 mg film-coated tablets, PTM Tenofovir DF, Viread 163 mg film-coated tablets, Viread 33 mg/g granules
Gilead Sciences Pty Limited
Hepatitis B Infection
1 trial -
Visilizumab
The First People's Hospital of Lianyungang
Immunotherapy
1 trial -
Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
Vortioxetine
The University of Hong Kong
Cannabis Use Disorder
1 trial -
Vortioxetine tablets
Takeda
Major Depressive Disorder
1 trial -
Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143
NovoThirteen
Participants with overweight or obesity, and type 2 diabetes
1 trial -
Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets
Istituto Gentili S.r.l.
Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)
1 trial -
XEOMIN 100 unités, poudre pour solution injectable
Pari Pharma GmbH
PANCREATIC FISTULA
1 trial -
XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,
Merz Pharmaceuticals GmbH
Lower limb spasticity
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources